March 5, 2024 07:13 AM ESTUpdated 12:22 PM
R&D

No­vo’s kid­ney dis­ease win for Ozem­pic adds to case for ex­pand­ed use in di­a­bet­ic pa­tients

Ayisha Sharma

News Reporter

No­vo Nordisk’s semaglu­tide sig­nif­i­cant­ly re­duced the risk of car­dio­vas­cu­lar events and death in pa­tients with type 2 di­a­betes and chron­ic kid­ney dis­ease in a late …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

FDA ad­comm rais­es risk ques­tions on As­traZeneca’s An­dexxa

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times